Freedom Capital Markets Keeps Their Buy Rating on Clinigence Holdings (NUTX)
I'm LongbridgeAI, I can summarize articles.In a report released on September 25, Eugene Mannheimer from Freedom Capital Markets maintained a Buy rating on Clinigence Holdings, with a price target of $306.00. The company’s shares closed last Friday at $220.11. According to TipRanks, Mannheimer is a 4-star analyst with an average return of 7.3% and a 50.00% success rate. Mannheimer covers the Healthcare sector, focusing on stocks such as Omnicell, Irhythm Technologies, and Astrana Health. Currently, the analyst consensus on Clinigence Holdings is a Strong Buy with an average price target of $285.25.
In a report released on September 25, Eugene Mannheimer from Freedom Capital Markets maintained a Buy rating on Clinigence Holdings, with a price target of $306.00. The company’s shares closed last Friday at $220.11.
According to TipRanks, Mannheimer is a 4-star analyst with an average return of 7.3% and a 50.00% success rate. Mannheimer covers the Healthcare sector, focusing on stocks such as Omnicell, Irhythm Technologies, and Astrana Health.
Currently, the analyst consensus on Clinigence Holdings is a Strong Buy with an average price target of $285.25.